ASH 2017 | A RESPONSE to ruxolitinib: update on 4-year trial follow-up
Jean-Jacques Kiladjian
An exciting update on the 4-year follow-up of the RESPONSE Trial (NCT01243944) was given by Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Paris Diderot University, Paris, France, at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition, held in Atlanta, GA. The RESPONSE trial compared the efficacy and safety of ruxolitinib vs. the best available therapy in patients with hydroxyurea-intolerant/resistant polycythemia vera (PV). Now, after conducting a 4-year follow-up on the study, Prof. Kiladijan discusses the results and the next steps.
Related videos
2:14
Key population-based registry studies in hematological oncology
Magnus Björkholm
2:38
MPN updates: personalized prognostication, novel treatments & more
Ruben Mesa
1:30
LCL161 for primary myelofibrosis: a new therapy in the field
Naveen Pemmaraju
6:57
Key updates in MPNs from ASH 2018
Claire Harrison
1:25
Highlights on myelofibrosis from ASH
Claire Harrison
